Stoke and Biogen publish data showing Dravet syndrome severity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Wall St rises as softer jobs data calms rate-hike fears
- Goldman's Garrett sees investors dialing back tech exposure into H2
- Oil falls to four-month low as US, Iran conclude talks in Doha
- Bond prices and stocks rally on softer payrolls, dollar falls
- Meta Platforms stock surges 8% on cloud business plans
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral
November 17, 2025 7:30 AM ESTDespite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development
Findings underscore the urgent need for new medicines that target the underlying genetic cause of Dravet syndrome to improve long-term outcomes
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS... More
